Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • wanna_million wanna_million Dec 16, 2012 9:30 AM Flag

    Lung and Prostate Cancer Drugs to be watched in 2013

    OncoGenex and Teva are evaluating OGX-011, an antisense cancer drug created with our technology in three phase 3 studies, and they remain on track to report phase 3 data in prostate cancer this next year.

    OncoGenex is also evaluating another antisense drug that we licensed to them, OGX-427, in phase 2 studies in patients with prostate and metastatic bladder cancers. We are finishing the phase 2 evaluation of our EIF4E inhibitor in patients with lung and prostate cancers. We expect to report data from those studies next year.

 
ISIS
55.43-0.70(-1.25%)Jul 6 4:00 PMEDT